Reagent for detecting avian leukosis virus, nano-enzyme immunochromatography test strip and application of nano-enzyme immunochromatography test strip
By developing monoclonal antibodies and nanoenzyme immunochromatographic test strips for the p27 protein of avian leukosis virus, the problems of the complexity and time-consuming nature of existing detection methods have been solved, and rapid detection with high sensitivity and specificity has been achieved, which is suitable for portable detection of avian leukosis virus.
Patent Information
- Application Number
- CN202511222926.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-29
- Publication Date
- 2025-10-03
- Estimated Expiration
- 2045-08-29
AI Technical Summary
Existing avian leukosis virus detection methods are complex, time-consuming, and highly equipment-dependent, and lack portable and efficient detection tools.
A monoclonal antibody and nanoenzyme immunochromatographic test strip based on the p27 protein of avian leukosis virus was developed. Specific monoclonal antibodies A and B were used in combination with nanoenzyme labeling technology to achieve rapid and simple virus and protein detection.
It achieves high sensitivity and specificity for the detection of avian leukosis virus, with the minimum virus detection amount being 12.5 TCID50/mL and the minimum protein detection amount being 0.2 ng/mL, and there being no cross-reaction, making it suitable for rapid on-site screening.
Smart Images

Figure CN120741854A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of immunology, and more specifically to a reagent for detecting avian leukosis virus (ALV) capsid protein (p27 protein), a nano enzyme immunochromatographic test strip, and applications thereof. Background Art
[0002] Avian leukosis (AL) is a chronic malignant tumor caused by the avian leukosis virus (ALV), characterized by abnormal proliferation of lymphoid tissue. As a major pathogen threatening the global poultry industry, ALV exhibits biological characteristics such as high vertical transmission efficiency, a long incubation period, and continuous toxin excretion after infection, posing a threat throughout the entire poultry farming cycle.
[0003] ALV belongs to the genus Alpharetrovirus in the family Retroviridae and is a single-stranded, positive-sense RNA virus. Currently, 11 ALV subtypes, including AK, have been identified, of which seven, including AE, J, and K, are capable of infecting chickens. Notably, subtypes A, B, and J exhibit strong pathogenicity, with subtype J, in particular, becoming the most prevalent ALV subtype in my country's poultry industry. The ALV genome is approximately 7.2 kb long and contains three major open reading frames (ORFs). From a 5' to 3' orientation, they are: the capsid protein gene (gag), which encodes the viral core structural proteins; the polymerase gene (pol), which encodes key enzymes such as reverse transcriptase and integrase; and the envelope glycoprotein gene (env), which encodes the envelope protein that determines the viral host tropism. The p27 protein, encoded by the gag gene, is a major component of the viral core capsid and is highly conserved across subtypes. It contains multiple easily detectable viral antigenic sites and exhibits strong immunogenicity, making it a key marker in virological research and clinical diagnosis.
[0004] Currently, the fundamental strategy for preventing this disease in my country is phased detection and evolutionary eradication in breeder chickens. Therefore, diagnostic work for this virus is particularly urgent. ALV detection methods primarily include pathogenic and serological testing, including virus isolation, indirect immunofluorescence, PCR, loop-mediated isothermal amplification (LAMP), and ELISA. Despite significant improvements, these diagnostic methods still suffer from complex procedures, time-consuming processes, and strong equipment dependence. Therefore, the development of more efficient and portable detection tools is urgently needed. Summary of the Invention
[0005] An object of the present invention is to solve at least the above problems and to provide at least the advantages which will be described hereinafter.
[0006] Another object of the present invention is to provide a reagent and nano enzyme immunochromatographic test strip for detecting avian leukosis virus (ALV) capsid protein (p27 protein) and their applications.
[0007] In order to achieve these purposes and other advantages according to the present invention, a reagent for detecting avian leukosis virus is provided, characterized in that it comprises a capture antibody and a detection antibody; wherein, When the capture antibody is monoclonal antibody A, the detection antibody is monoclonal antibody B; or when the capture antibody is monoclonal antibody B, the detection antibody is monoclonal antibody A; The heavy chain variable region of the monoclonal antibody A comprises the amino acid sequence shown in SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 2; The heavy chain variable region of the monoclonal antibody B comprises the amino acid sequence shown in SEQ ID NO: 5, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 6; The antigen-binding fragment is a Fab fragment, a F(ab)2 fragment or a single-chain Fv fragment.
[0008] Preferably, in the reagent for detecting avian leukosis virus, the amino acid sequences of the heavy chain variable region CDR1, CDR2, and CDR3 of the monoclonal antibody A are ATPSQPTI, FILEILIL, and QEREVTTAWPGFLT, respectively; and the amino acid sequences of the light chain variable region CDR1, CDR2, and CDR3 of the monoclonal antibody A are KSVSTSGYSY, LVS, and QHIRELTR, respectively; The heavy chain variable region CDR1, CDR2, and CDR3 of the monoclonal antibody B are VTHSLATP, LILTMVVL, and QDMMVTTWGLTT, respectively; the light chain variable region CDR1, CDR2, and CDR3 of the monoclonal antibody B are QSLLNSGNQKNY, WAS, and QNDYDYPLT, respectively.
[0009] The present invention also provides a nano enzyme immunochromatographic test strip, which comprises a PVC base plate and a sample pad, a conjugation pad, a nitrocellulose membrane and a water-absorbing pad which are overlapped in sequence, wherein the nitrocellulose membrane is provided with a detection line and a quality control line; The conjugate pad is coated with a capture antibody labeled with a nanozyme, and the detection line is coated with a detection antibody; The capture antibody and detection antibody are respectively the capture antibody and detection antibody contained in the above-mentioned reagent for detecting avian leukosis virus; The quality control line is coated with goat anti-mouse IgG antibody.
[0010] Preferably, in the nanoenzyme immunochromatographic test strip, the labeling concentration of the nanoenzyme-labeled capture antibody is 60 μg / mL; the concentration of the detection antibody coated on the detection line is 1 mg / mL; and the concentration of the goat anti-mouse IgG coated on the quality control line (C) is 1 mg / mL.
[0011] The present invention also provides an application of the nanoenzyme immunochromatographic test strip in detecting avian leukosis virus, wherein the detection sample is a cloacal swab, meconium, egg white or serum of a poultry.
[0012] The present invention has at least the following beneficial effects: 1. The present invention first screened and obtained a monoclonal hybridoma cell line encoding the p27 protein of avian leukosis virus, then obtained a specific monoclonal antibody, and obtained the antibody variable region gene sequence through nested PCR amplification (which can be subsequently obtained using genetic engineering or protein engineering methods). Furthermore, based on the monoclonal antibody specific for the p27 protein of avian leukosis virus, the present invention developed a convenient, rapid, accurate, highly sensitive, and highly specific nanoenzyme immunochromatographic test strip for detecting avian leukosis virus. 2. This invention has developed a nanozyme antigen detection test strip for avian leukosis virus based on immunochromatographic technology, achieving "one-step" detection and suitable for rapid on-site screening. This test strip combines the catalytic and signal amplification properties of nanomaterials, optimizing the shortcomings of traditional methods and improving the sensitivity of avian leukosis virus detection. The minimum detection amount of the virus is 12.5 TCID 50 / mL, and the minimum detectable amount of protein was 0.2 ng / mL.
[0013] Other advantages, objectives and features of the present invention will be reflected in part from the following description and will be understood by those skilled in the art through study and practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is a diagram showing the results of SDS-PAGE identification after the purification of the avian leukosis virus p27 protein in Example 1 of the present invention, M: protein marker; 1: purified recombinant pCold I-p27 protein.
[0015] Figure 2 This is a schematic diagram of the structure of the avian leukosis virus test strip in Example 2 of the present invention.
[0016] Figure 3 This is a schematic diagram of determining the detection results of the avian leukosis virus test strip in Example 3 of the present invention.
[0017] Figure 4 This is a graph showing the results of virus sensitivity testing using the nanoenzyme immunochromatographic test strip for avian leukosis virus in Example 3 of the present invention.
[0018] Figure 5 This is a graph showing the sensitivity test results of the avian leukosis virus nanoenzyme immunochromatographic test strip to p27 protein in Example 3 of the present invention.
[0019] Figure 6 This is a diagram of the negative anal swab test results in Example 3 of the present invention.
[0020] Figure 7 This is a diagram showing the specificity detection results of the avian leukosis virus test strip in Example 3 of the present invention, NC: sample diluent. DETAILED DESCRIPTION
[0021] The present invention will be further described in detail below with reference to the accompanying drawings and embodiments so that those skilled in the art can implement the invention with reference to the description.
[0022] It should be understood that terms such as “having”, “including” and “comprising” used herein do not preclude the existence or addition of one or more other elements or combinations thereof.
[0023] It should be noted that the experimental methods described in the following embodiments are conventional methods unless otherwise specified, and the reagents and materials can be obtained from commercial channels unless otherwise specified.
[0024] In the description of the present invention, the terms "horizontal", "longitudinal", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside" and the like to indicate orientations or positional relationships are based on the orientations or positional relationships shown in the accompanying drawings and are only for the convenience of describing the present invention and simplifying the description. They do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operate in a specific orientation, and therefore should not be understood as limiting the present invention.
[0025] The present invention specifically relates to a monoclonal antibody specific for the capsid protein (p27) of avian leukosis virus (ALV) and its application - a nanoenzyme immunochromatographic test strip containing the antibody. The amino acid sequences of the heavy chain variable regions of the monoclonal antibody or antigen-binding fragments one and two are shown in SEQ ID NO: 1 and 5, respectively; the amino acid sequences of the light chain variable regions are shown in SEQ ID NO: 2 and 6, respectively. Based on the double antibody sandwich principle, the present invention constructs an ALV nanoenzyme detection test strip. The test strip has significant technical advantages: ① It has strong specificity and can accurately identify ALV, and has no cross-reaction with Newcastle disease virus, Marek's disease virus, infectious bursal disease virus, fowlpox virus, infectious laryngotracheitis virus, and avian influenza virus; ② It has high sensitivity, and the minimum detection amount of the virus is 12.5 TCID 50 / mL, and the minimum detection amount of protein was 0.2ng / mL, showing good detection sensitivity.
[0026] In a first aspect of the present invention, a monoclonal hybridoma cell line encoding the p27 protein of avian leukosis virus (ALV) is screened to obtain a specific monoclonal antibody, and the variable region gene sequence of the antibody is obtained by nested PCR amplification (which can be subsequently obtained using genetic engineering or protein engineering methods); the monoclonal antibody is selected from monoclonal antibody A (monoclonal antibody or antigen-binding fragment 1) or monoclonal antibody B (monoclonal antibody or antigen-binding fragment 2); the heavy chain variable region of monoclonal antibody A comprises the amino acid sequence set forth in SEQ ID NO:1, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:2; the heavy chain variable region of monoclonal antibody B comprises the amino acid sequence set forth in SEQ ID NO:5, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:6; The antigen-binding fragment is a Fab fragment, a F(ab)2 fragment or a single-chain Fv fragment.
[0027] The amino acid sequences of the heavy chain variable region CDR1 (SEQ ID NO: 9), CDR2 (SEQ ID NO: 10), and CDR3 (SEQ ID NO: 11), and the light chain variable region CDR1 (SEQ ID NO: 12), CDR2, and CDR3 (SEQ ID NO: 13) of the monoclonal antibody or antigen-binding fragment 1 (monoclonal antibody A) are shown in Table 1: Table 1 Amino acid sequences of CDR1, CDR2, and CDR3 of the heavy and light chain variable regions of monoclonal antibody A The amino acid sequences of the heavy chain variable region CDR1 (SEQ ID NO: 14), CDR2 (SEQ ID NO: 15), and CDR3 (SEQ ID NO: 16), and the light chain variable region CDR1 (SEQ ID NO: 17), CDR2, and CDR3 (SEQ ID NO: 18) of the second monoclonal antibody or antigen-binding fragment (monoclonal antibody B) are shown in Table 2: Table 2 Amino acid sequences of CDR1, CDR2, and CDR3 of the heavy and light chain variable regions of monoclonal antibody B In a second aspect, a biomaterial related to the above-mentioned monoclonal antibody or antigen-binding fragment thereof that specifically binds to the p27 protein of avian leukosis virus is provided, wherein the biomaterial is any one of the following: (a) a nucleic acid molecule comprising a sequence encoding the heavy chain variable region and / or light chain variable region of the monoclonal antibody or antigen-binding fragment that specifically binds to avian leukosis virus p27 protein; (b) an expression cassette comprising the nucleic acid molecule of (a); (c) a recombinant vector comprising the nucleic acid molecule of (a) or the expression cassette of (b); (d) a recombinant eukaryotic cell containing the nucleic acid molecule of (a), the expression cassette of (b), or the recombinant vector of (c); (e) A host cell containing the nucleic acid molecule of (a), the expression cassette of (b), or the recombinant vector of (c).
[0028] Among them, the nucleic acid sequence encoding the heavy chain variable region of monoclonal antibody A is shown in SEQ ID NO: 3, and the nucleic acid sequence of the light chain variable region is shown in SEQ ID NO: 4; the nucleic acid sequence encoding the heavy chain variable region of monoclonal antibody B is shown in SEQ ID NO: 7, and the nucleic acid sequence of the light chain variable region is shown in SEQ ID NO: 8.
[0029] The heavy chain constant regions of the above-mentioned ALV p27 protein monoclonal antibodies are all of IgG1 type, and the light chain constant regions are all of Kappa type.
[0030] In a third aspect, the present invention provides the use of the monoclonal antibody or antigen-binding fragment specifically binding to ALV p27 protein, the DNA encoding the monoclonal antibody or antigen-binding fragment, the vector, and the host cell in preparing an avian leukosis virus detection reagent.
[0031] In a fourth aspect, the present invention provides a reagent for detecting avian leukosis virus, comprising a capture antibody and a detection antibody; wherein, The capture antibody and the detection antibody are independently selected from at least one of the above-mentioned monoclonal antibody A and monoclonal antibody B; The capture antibody is selected from at least one of the monoclonal antibody or antigen-binding fragment 1 that specifically binds to ALV p27 protein (monoclonal antibody A) and the monoclonal antibody or antigen-binding fragment 2 that specifically binds to ALV p27 protein (monoclonal antibody B); Alternatively, the detection antibody is selected from at least one of the monoclonal antibody or antigen-binding fragment 1 that specifically binds to ALV p27 protein (monoclonal antibody A) and the monoclonal antibody or antigen-binding fragment 2 that specifically binds to ALV p27 protein (monoclonal antibody B); Alternatively, the capture antibody is the monoclonal antibody or antigen-binding fragment 1 (monoclonal antibody A) that specifically binds to ALV p27 protein, and the detection antibody is the monoclonal antibody or antigen-binding fragment 2 (monoclonal antibody B) that specifically binds to ALV p27 protein; Alternatively, the capture antibody is the monoclonal antibody or antigen-binding fragment 2 (monoclonal antibody B) that specifically binds to ALV p27 protein, and the detection antibody is the monoclonal antibody or antigen-binding fragment 1 (monoclonal antibody A) that specifically binds to ALV p27 protein. In a fifth aspect, the present invention provides a nanoenzyme immunochromatographic test strip for rapid detection of avian leukosis virus, wherein the test strip contains the above-mentioned reagent for detecting avian leukosis virus. Specifically, the test strip includes a PVC base, a sample pad, a conjugation pad, a nitrocellulose membrane, and a water-absorbing pad, wherein the sample pad, conjugation pad, nitrocellulose membrane, and water-absorbing pad are sequentially overlapped on the PVC base; a detection line T and a quality control line C are provided on the nitrocellulose membrane, wherein the detection line T is arranged at one end close to the conjugation pad, and the quality control line C is arranged at one end close to the water-absorbing pad; the conjugation pad is sprayed with the capture antibody labeled with nanoenzyme, and the detection line T is coated with the detection antibody; the quality control line C is coated with goat anti-mouse IgG.
[0032] Capture antibodies and detection antibodies specifically include the following: The conjugate pad is sprayed with the above-mentioned monoclonal antibody 1 specifically binding to ALV p27 protein (monoclonal antibody A) labeled with nanozyme, and the detection line T is coated with the above-mentioned monoclonal antibody 2 specifically binding to ALV p27 protein (monoclonal antibody B); Alternatively, the conjugate pad is sprayed with the aforementioned monoclonal antibody 2 specifically binding to ALV p27 protein (monoclonal antibody B) labeled with nanozyme, and the detection line T is coated with the aforementioned monoclonal antibody 1 specifically binding to ALV p27 protein (monoclonal antibody A); Alternatively, the conjugate pad is sprayed with the aforementioned monoclonal antibody specifically binding to ALV p27 protein (monoclonal antibody A) labeled with nanozyme, and the detection line T is coated with other existing monoclonal antibodies specifically binding to ALV; Alternatively, the conjugate pad is sprayed with the aforementioned ALV p27 protein specific binding monoclonal antibody 2 (monoclonal antibody B) labeled with nanozyme, and the detection line T is coated with other existing monoclonal antibodies that specifically bind to ALV; Alternatively, the conjugate pad is sprayed with other existing monoclonal antibodies specifically binding to ALV that are labeled with nanozymes, and the detection line T is coated with the above-mentioned monoclonal antibody specifically binding to ALV p27 protein (monoclonal antibody A); Alternatively, the conjugate pad is sprayed with other existing monoclonal antibodies specifically binding to ALV that are labeled with nanozymes, and the detection line T is coated with the above-mentioned monoclonal antibody second specifically binding to ALV p27 protein (monoclonal antibody B).
[0033] The nanozyme-labeled capture antibody is prepared by the following steps: washing the nanozyme with deionized water; after centrifugation, discarding the supernatant; resuspending the precipitate with MES buffer solution, adding EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and NHS (N-hydroxysuccinimide), mixing, and placing it on a shaker for activation; after activation, washing with MES buffer solution, and then resuspending with MES buffer solution to obtain an activated nanozyme; ALV p27 protein monoclonal antibody A is incubated with the activated nanozyme solution overnight; Tris buffer is added to terminate the reaction; after magnetic separation, resuspending with protection buffer to obtain a nanozyme ALV p27 protein monoclonal antibody probe.
[0034] Spray the above-mentioned nanozyme ALV p27 protein monoclonal antibody probe onto the conjugate pad; The concentration of the nanozyme is 5 mg / mL; The concentration of the Tris buffer is 0.05 mol / L and the pH is 7.2; The protection buffer is BSA-Tirs with a mass concentration of 5%; The composition of the ALV p27 protein monoclonal antibody A nanozyme labeling solution is as follows: each 1 mL of the nanozyme labeling solution contains 60 μg of ALV p27 protein monoclonal antibody A.
[0035] Preferably, the detection line T is coated with 1 mg / mL of ALV p27 protein monoclonal antibody B.
[0036] Preferably, the quality control line C is coated with 1 mg / mL goat anti-mouse IgG.
[0037] The preparation method of the nanoenzyme immunochromatographic test strip comprises the following steps: (1) Preparing a binding pad coated with ALV p27 protein monoclonal antibody A labeled with nanozyme; (2) ALV p27 protein monoclonal antibody B (1 mg / mL) and goat anti-mouse IgG antibody (1 mg / mL) were sprayed onto the nitrocellulose membrane at intervals of 5 to 8 mm, serving as the test line T and the quality control line C, respectively; (3) The sample pad, conjugate pad, nitrocellulose membrane and absorbent pad were overlapped on the PVC base plate in sequence to obtain a nano enzyme immunoassay test strip for detecting avian leukosis virus.
[0038] The beneficial effects of the present invention are: The present invention screens and obtains monoclonal antibodies A and B against the p27 protein of avian leukosis virus, which can be used as capture antibodies or detection antibodies to detect avian leukosis virus.
[0039] The nano enzyme immunochromatographic test strip for detecting avian leukosis virus provided by the present invention can be used for the specific detection of avian leukosis virus. At the same time, the test strip can detect the virus in the culture with a minimum limit of 12 TCID 50 / mL, the minimum detection amount of protein is 0.2ng / mL, and there is no cross reaction with Newcastle disease virus, Marek's disease virus, infectious bursal disease virus, fowlpox virus, infectious laryngotracheitis virus, and avian influenza virus.
[0040] The test strip prepared by the present invention has the advantages of strong specificity, high sensitivity, simple operation, short detection time, intuitive result display, etc., and provides an instant detection method for on-site or laboratory detection of avian leukosis virus.
[0041] Example 1 Preparation of ALV p27 protein monoclonal antibody and amplification of antibody sequence 1.1 Preparation of ALV p27 protein Primers were designed based on the sequence of GenBank accession number: KU375453. The PCR amplification product was inserted into the prokaryotic expression vector pCold I. The recombinant plasmid was named pCold I-p27 and transformed into Escherichia coli BL21 (DE3). The engineered bacteria expressing ALV p27 protein were inoculated into 100 mL of LB containing kanamycin resistance. When the OD600 was approximately 0.8, IPTG was added at a final concentration of 1 mmol / L to induce expression. After 5 hours, the precipitate was collected by centrifugation at 12000 rpm for 10 minutes. The precipitate was resuspended in an appropriate amount of PBS and sonicated for 10 minutes (sonication for 3 seconds, stop for 3 seconds). After sonication, the supernatant was centrifuged at 12000 rpm for 10 minutes at 4°C. The supernatant was collected and purified by nickel column. The purified product was ALV p27 protein and identified by SDS-PAGE. The identification results are as follows: Figure 1 The protein samples were assayed for protein concentration using a BCA kit (Biyuntian), aliquoted, and stored at -80°C until use.
[0042] 1.2 Preparation of monoclonal antibodies against ALV p27 protein and amplification of antibody sequences Babl / c mice were immunized with 30 μg of purified ALV p27 recombinant protein per mouse. For the first immunization, the ALV p27 protein was mixed with an equal volume of Freund's complete adjuvant, emulsified, and injected subcutaneously at multiple points on the back. Booster immunizations were performed every two weeks for a total of four immunizations. For the booster immunizations, the ALV p27 recombinant protein was mixed with an equal volume of Freund's incomplete adjuvant, emulsified, and the immunization method was the same as the first immunization. One week after the fourth immunization, the mice were tail-clipped and blood was collected for antibody titer determination by ELISA. Splenocytes from the mouse with the highest antibody titer were obtained and fused according to conventional methods to screen for hybridoma cell lines that specifically secrete monoclonal antibodies against the ALV p27 protein. After expansion and culture, the cells were injected into the mouse peritoneal cavity, and the ascites fluid obtained was subjected to affinity chromatography using the PIERCE NAb™ Protein G Spin Purification Kit.
[0043] RNA was extracted from positive hybridoma cells and reverse transcribed into cDNA using either oligo-dT or random primers (PrimeScript II 1st Strand cDNA Synthesis Kit, TAKARA, 6210A). The variable region genes were amplified using nested PCR. First, the cDNA was used as a template to amplify the variable region genes using first-round mouse IgG and κ light chain primers. Second, the first-round product was used as a template to amplify the variable region genes using second-round mouse IgG and κ light chain primers. The PCR reaction system consisted of 25 μL of PrimeSTARMax Premix (2×), 0.2 μL of each primer, 1 μL of cDNA, and ddH2O to 50 μL. The reaction protocol was as follows: pre-denaturation at 98°C for 2 min, followed by 30 cycles of denaturation at 98°C for 10 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s, followed by extension at 72°C for 10 min. Primers for antibody variable region gene amplification were referenced in the literature (von Boehmer, L., Liu, C., Ackerman, S., Gitlin, AD, Wang, Q., Gazumyan, A., Nussenzweig, MC, 2016. Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nature protocols 11, 1908-1923). After amplification, the heavy and kappa light chain variable region genes were electrophoresed on a 1% agarose gel. The target fragments were excised and sequenced. The sequencing results were compared with the ImmunoRepository (IMGT) library, confirming that the amplified sequences were DNA sequences of the heavy and light chain variable regions of monoclonal antibodies. Specifically, the DNA sequences encoding the heavy chain variable regions of the ALV p27 protein A and B monoclonal antibodies are shown in SEQ ID NOs: 3 and 7, respectively; the DNA sequences encoding the light chain variable regions of the ALV p27 protein A and B monoclonal antibodies are shown in SEQ ID NOs: 4 and 8, respectively. The amino acid sequences of the heavy chain variable regions of the ALV p27 protein A and B monoclonal antibodies are shown in SEQ ID NOs: 1 and 5, respectively; and the amino acid sequences of the light chain variable regions of the ALV p27 protein A and B monoclonal antibodies are shown in SEQ ID NOs: 2 and 6, respectively.
[0044] The amino acid sequences of the heavy chain and light chain variable regions CDR1, CDR2, and CDR3 of monoclonal antibody A are shown in Table 1. The amino acid sequences of the heavy chain and light chain variable regions CDR1, CDR2, and CDR3 of monoclonal antibody B are shown in Table 2.
[0045] Example 2 Preparation of Nanoenzyme Immunochromatographic Test Strips for Avian Leukosis Virus 2.1 Preparation of nanozyme-ALV p27 protein monoclonal antibody probe Take 500 μL of nanozyme solution (preferably prepared by referring to Publication 202411276039.6 A nanozyme and its preparation method and application), the concentration of the nanozyme is 5 mg / mL, and wash three times with 1 mL of deionized water; after centrifugation, discard the supernatant; resuspend the precipitate with 1 mL of MES buffer solution, the pH of 50 mM MES buffer solution is 6.0, and add 10 μL of EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and 20 μL of NHS (N-hydroxysuccinimide), mix well, and place in a shaker for activation for 30 minutes; the concentration of EDC and NHS is 20 mg / mL; the shaker speed is 70 rpm; after activation, wash once with 1 mL of MES buffer solution, and then resuspend with 500 μL of MES buffer solution to obtain activated nanozyme; take 50 μg of ALV The p27 protein monoclonal antibody A was incubated with the activated nanozyme solution overnight at 4°C; the reaction was terminated by incubating with 0.05 mol / L Tris buffer at pH 7.2 at room temperature for 30 minutes; after magnetic separation, the solution was resuspended with 0.5 mL of 5% BSA Tris buffer to obtain the nanozyme ALV monoclonal antibody probe.
[0046] 2.2 Preparation of Nanozyme Binding Pad The prepared nanozyme-ALV p27 protein monoclonal antibody A probe was evenly sprayed on the conjugate pad using a film sprayer, placed in a 37°C oven to dry for 2-3 hours, and sealed for storage.
[0047] 2.3 Preparation of nitrocellulose membrane Dilute ALV p27 protein monoclonal antibody B and goat anti-mouse IgG antibody to 1 mg / mL, spray them on nitrocellulose membrane with a spacing of 5 to 8 mm, as the test line (T) and quality control line (C), respectively. After the lines are drawn, place them at 37°C to 38°C to dry for 2 to 3 hours.
[0048] 2.4. Assembly of test strips The sample pad, conjugate pad, nitrocellulose membrane and absorbent pad are connected on the PVC base plate in sequence to obtain a test strip. The test strip is cut into strips according to the size of the test strip card, and then the cut test strips are loaded into the test strip card. The structural diagram of the test strip is shown in FIG. Figure 2 shown.
[0049] Example 3 Application of Nano-enzyme Immunochromatographic Test Strips for Avian Leukosis Virus 3.1 How to use the test strips 3.1.1 Sample processing (1) Samples include: poultry cloaca swab, meconium, egg white or serum samples.
[0050] (2) Add the sample to a sample treatment tube containing 1 mL of sample treatment solution. Shake the tube back and forth to dissolve the sample and mix thoroughly with the sample treatment solution. Then let it stand for 1 minute to allow the undissolved sample to precipitate. The sample treatment solution is a 0.01 mol / L PBS solution with a pH of 7.4.
[0051] 3.1.2 Sample testing Remove the sealed test strip and place it on a dry, stable surface. Use a pipette to draw an appropriate amount of the supernatant from 3.1.1 and slowly add 6-7 drops (approximately 100-150 μL) to the sample well. Start chromatography, time for 10 minutes, and observe the results. To amplify the detection signal, add a peroxidase substrate, such as DAB, after 10 minutes. The enzymatic activity of the nanozyme catalyzes a chemical reaction with DAB to produce a large amount of brown precipitate.
[0052] 3.1.3. Judgment (1) Two brown bands (T: test line, C: control line) appear on the test strip, which is considered positive (see Figure 3 A).
[0053] (2) If only one brown band (C: quality control line) appears on the test strip, it is judged as negative (see Figure 3 B).
[0054] (3) If no brown strip appears at the quality control line of the test strip, it is considered invalid (see Figure 3 C).
[0055] 3.2. Sensitivity of test strips The titer is 10 5.5 TCID 50 / mL of ALV virus was diluted 1:200 times and then diluted 2 times, and then the sensitivity test was performed using the avian leukosis virus nanoenzyme immunochromatographic test strip established by the present invention.
[0056] The results showed that when the avian leukosis virus nanoenzyme immunochromatographic test strip was used to detect 12.5 TCID 50 / mL of virus solution, the test result is positive; when the avian leukosis virus nanoenzyme immunochromatographic test strip is used to detect 6.25 TCID 50 / mL of virus solution, the test result is negative ( Figure 4 The above results show that the sensitivity of the test strip prepared in this example for detecting avian leukosis virus is 12.5 TCID 50 / mL.
[0057] The purified p27 protein with a concentration of 0.1 mg / mL was diluted 2-fold to obtain concentrations of 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.20, 0.10, and 0.05 ng / mL, respectively. When the p27 protein dilution concentration was 0.2 ng / mL, the avian leukosis virus nanozyme immunochromatographic test strip established by the present invention tested positive, and the protein sample with a concentration of 0.1 ng / mL tested negative ( Figure 5 ). The above results show that the sensitivity of the test strip prepared in this example for detecting p27 protein is 0.2 ng / mL.
[0058] 3.3 Specificity of test strips Ten negative anal swabs were tested with test strips, numbered A1 to A10. The test results showed that a brown band appeared on the quality control line C, and no band was seen at the T line, indicating that the test result was negative ( Figure 6 The test strips were used to detect different avian viruses, including Newcastle disease virus (NDV), Marek's disease virus (MDV), infectious bursal disease virus (IBDV), fowlpox virus (FPV), infectious laryngotracheitis virus (ILTV), and avian influenza virus (AIV). The results showed that only ALV was positive, while the others were negative, indicating that the method established by the present invention can specifically identify ALV. Figure 7 As shown, the test strips established by the present invention have strong specificity.
[0059] SEQ ID NO: 1 PGASGGYPARLLATPSQPTIYTGCSRGLDRDLSGLDGFILEILILSTMRSSRARPHLLQTNPPAQPTCSSAAWPLRTLRSISVQEREVTTAWPGFLTGAKGLWSLSLQ SEQ ID NO:2 GTISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGGPSWKSN SEQ ID NO:3 CCTGGGGCTTCAGGAGGATATCCTGCAAGGCTTCTGGCTACACCTTCACAACCTACTATATACACTGGGTGCAGCAGAGGCCTGGACAGGGACTTGAGTGGATTGGATGGATTTATCCTGGAAATTCTAATACTGAGTACAATGAGAAGTTCAAGGGCAAGGCCACACTTACTGCAGACAAATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGGCCTCTGAGGACTCTGCGATCTATTTCTGTGCAAGAGAGGGAGGTAACTACGGCCTGGCCTGGTTTCCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG SEQ ID NO:4 GGCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGGAGCTTACACGTTCGGAGGGGGGACCAAGCTGGAAATCAAAC SEQ ID NO:5 PGASGRYPARLLVTHSLATPSTGCNRAMERTLSGLDLLILTMVVLTTTRTSRARPHWLETCHPAQPTWNSSVWHLRTLQSITVQDMMV SEQ ID NO:6 VTMSCKSSQSLLNSGNQKNYLTWYQQRPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYDYPLTFGT SEQ ID NO:7 CCTGGAGCTTCAGGAAGATATCCTGCAAGGCTTCTGGTTACTCATTCACTGGCTACACCATcAACTGGGTGCAACAGAGCCATGGAAAGAACCTTGAGTGGATTGGACTTATTAATCCTTACAATGGTGGTGCTAACTACAACCAGAACTTCAAGGGCAAGGCCACATTGGCTGGAGACATGTCATCCAGCACAGCCTACATGGAACTCCTCAGTCTGGCATCTGAGGACTCTGCAGTCTATTACTGTGCAAGATATGATGGTTACTACGTGGGGTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAG SEQ ID NO:8 GTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACCTGGTACCAGCAGAGACCAGGGCAGCCTCCTAAACTATTGATCTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGATTATGATTATCCGCTCACGTTCGGTACTGGGACCAAGCTGGAGCTGAAAC SEQ ID NO:9 ATPSQPTI SEQ ID NO:10 FILEILIL SEQ ID NO:11 QEREVTTAWPGFLT SEQ ID NO:12 KSVSTSGYSY SEQ ID NO:13 QHIRELTR SEQ ID NO:14 VTHSLATP SEQ ID NO:15 LILTMVVL SEQ ID NO:16 QDMMVTTWGLTT SEQ ID NO: 17 QSLLNSGNQKNY SEQ ID NO: 18 QNDYDYPLT The number of devices and processing scales described herein are intended to simplify the description of the present invention. Applications, modifications, and variations of the present invention will be readily apparent to those skilled in the art.
[0060] Although the embodiments of the present invention have been disclosed above, they are not limited to the applications listed in the description and implementation methods. They can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily implemented. Therefore, without departing from the general concept defined by the claims and the scope of equivalents, the present invention is not limited to the specific details and illustrations shown and described herein.
Claims
1. A reagent for detecting avian leukosis virus, characterized in that: Comprising a capture antibody and a detection antibody; wherein, When the capture antibody is monoclonal antibody A, the detection antibody is monoclonal antibody B; or when the capture antibody is monoclonal antibody B, the detection antibody is monoclonal antibody A; The heavy chain variable region of the monoclonal antibody A comprises the amino acid sequence shown in SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 2; The heavy chain variable region of the monoclonal antibody B comprises the amino acid sequence shown in SEQ ID NO: 5, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 6; The antigen-binding fragment is a Fab fragment, a F(ab)2 fragment or a single-chain Fv fragment.
2. The reagent for detecting avian leukosis virus according to claim 1, wherein The amino acid sequences of the heavy chain variable region CDR1, CDR2, and CDR3 of the monoclonal antibody A are ATPSQPTI, FILEILIL, and QEREVTTAWPGFLT, respectively; the amino acid sequences of the light chain variable region CDR1, CDR2, and CDR3 of the monoclonal antibody A are KSVSTSGYSY, LVS, and QHIRELTR, respectively; The heavy chain variable region CDR1, CDR2, and CDR3 of the monoclonal antibody B are VTHSLATP, LILTMVVL, and QDMMVTTWGLTT, respectively; the light chain variable region CDR1, CDR2, and CDR3 of the monoclonal antibody B are QSLLNSGNQKNY, WAS, and QNDYDYPLT, respectively.
3. A nano enzyme immunochromatographic test strip, characterized in that: It includes a PVC base plate and a sample pad, a conjugation pad, a nitrocellulose membrane and a water-absorbing pad which are sequentially connected. The nitrocellulose membrane is provided with a detection line and a quality control line. The conjugation pad is coated with a capture antibody labeled with a nanozyme, and the detection line is coated with a detection antibody. The capture antibody and the detection antibody are respectively the capture antibody and the detection antibody contained in the reagent for detecting avian leukosis virus according to claim 1; The quality control line is coated with goat anti-mouse IgG antibody.
4. The nanoenzyme immunochromatographic test strip according to claim 3, wherein The labeling concentration of the nanozyme-labeled capture antibody is 60 μg / mL; the detection antibody concentration of the detection line is 1 mg / mL; and the goat anti-mouse IgG concentration of the quality control line is 1 mg / mL.
5. Use of the nanoenzyme immunochromatographic test strip according to any one of claims 3 to 4 in detecting avian leukosis virus, characterized in that: The test samples are poultry cloacal swabs, meconium, egg white or serum.
Citation Information
Patent Citations
Nano enzyme as well as preparation method and application thereof
CN119143190A
Recombinant antibody resisting influenza a virus nucleoproteins as well as preparation method and application of recombinant antibody
CN105601744A
Latex immunochromatography test strip for rapidly detecting swine transmissible gastroenteritis coronavirus and preparation method of latex immunochromatography test strip
CN116699130A
K subgroup avian leukosis virus colloidal gold test strip, preparation method and application
CN118150824A
Latex duplex immunochromatography test strip for rapidly identifying and detecting TGEV and PEDV and preparation method of latex duplex immunochromatography test strip
CN119510750A
Cited By
Reagent for detecting porcine rotavirus, nano-enzyme immunochromatography test strip and application of nano-enzyme immunochromatography test strip
CN121299117A
